SCHEMBL3993938

SCHEMBL3993938

N=NNc1cccc(O)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
ALOX15 P16050 3/20 0.46
HSD17B10 Q99714 3/20 0.46
CA2 P00918 3/20 0.46
CDK2 P24941 2/20 0.46
EGFR P00533 2/20 0.46
FYN P06241 2/20 0.46
MMP9 P14780 2/20 0.46
RECQL P46063 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
ADAMTS4 O75173 1/20 0.46
CA1 P00915 1/20 0.46
MMP2 P08253 1/20 0.46
MMP8 P22894 1/20 0.46
CA6 P23280 1/20 0.46
MMP12 P39900 1/20 0.46
ADAMTS5 Q9UNA0 1/20 0.46
TRPA1 O75762 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15782762 0.73 DEPTOR (0.31)
SCHEMBL7802339 0.70 ALDH1A1 (0.52) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL17715571 0.70 HPGD (0.52) LMNAALDH1A1HPGDALOX15HSD17B10
Pyrogallol SCHEMBL3532 0.66
Pyrogallol SCHEMBL170157 0.66 ALDH1A1 (1.00) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL3567350 0.65 ERN1 (0.48) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL3567348 0.65 LMNA (0.46) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL16918790 0.65 CXCR1 (0.39) LMNAALDH1A1HPGDCA2EGFR
Boric Acid SCHEMBL14940655 0.65 HPGD (0.46) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL9055550 0.65 ALDH1A1 (0.50) LMNAALDH1A1HPGDALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797087-A4 CARBO- AND HETERO-CYCLIC ANTIBIOTICS AND USE THEREOF ULYSSES PHARMACEUTICAL PRODUCT (CA) 2009-06-03 EP disclosed
US-20080188499-A1 Carbo- and Hetero-Cyclic Antibiotics and Use Thereof ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) 2008-08-07 US disclosed
EP-1797087-A1 CARBO- AND HETERO-CYCLIC ANTIBIOTICS AND USE THEREOF Ulysses Pharmaceuticals Products Inc. (CA) 2007-06-20 EP disclosed
WO-2006032138-A1 CARBO- AND HETERO-CYCLIC ANTIBIOTICS AND USE THEREOF ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188499-A1 Carbo- and Hetero-Cyclic Antibiotics and Use Thereof SLC7A1, CYP2C19, ABCB11 LMNA 3823/4885ALDH1A1 2455/4885HPGD 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.